• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Roya Khosravi-Far, Ph.D.


  • Bucur O, Stancu AL, Goganau I, Petrescu SM, Pennarun B, Bertomeu T, Dewar R, Khosravi-Far R.Combination of bortezomib and mitotic inhibitors down-modulate Bcr-Abl and efficiently eliminates tyrosine-kinase inhibitor sensitive and resistant Bcr-Abl-positive leukemic cells.PLoS ONE. 2013;8(10):e77390.
  • Bucur O, Pennarun B, Stancu AL, Nadler M, Muraru MS, Bertomeu T, Khosravi-Far R.Poor antibody validation is a challenge in biomedical research: a case study for detection of c-FLIP.Apoptosis. 2013 Oct;18(10):1154-62.
  • Plati J, Bucur O, Khosravi-Far R.Apoptotic cell signaling in cancer progression and therapy.Integr Biol (Camb). 2011 Apr 1;3(4):279-96.
  • Singh A, Plati J, Khosravi-Far R.Harnessing the Tumor Suppressor Function of FOXO as an Alternative Therapeutic Approach in Cancer.Curr Drug Targets. 2011 Mar 28.
  • Dewar R, Chen ST, Yeckes-Rodin H, Miller K, Khosravi-Far R.Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.Cancer Biol Ther. 2011 Mar 15;11(6):552-8.
  • Kazerounian S, Duquette M, Reyes MA, Lawler JT, Song K, Perruzzi C, Primo L, Khosravi-Far R, Bussolino F, Rabinovitz I, Lawler J.Priming of the vascular endothelial growth factor signaling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase.Blood. 2011 Mar 4.
  • Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Sim T, Zhou W, Seeliger M, Cameron M, Azam M, Fletcher JA, Debiec-Rychter M, Mayeda M, Moreno D, Kung AL, Janne PA, Khosravi-Far R, Melo JV, Manley P, Adamia S, Wu C, Gray N, Griffin JD.Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR{alpha}, Kit, and Src kinases.Blood. 2010 May 27;115(21):4206-16.
  • Singh A, Ye M, Bucur O, Zhu S, Santos MT, Rabinovitz I, Wei W, Gao D, Hahn WC, Khosravi-Far R.Protein Phosphatase 2A Reactivates FOXO3a through a Dynamic Interplay with 14-3-3 and AKT.Mol Biol Cell. 2010 Mar;21(6):1140-52.
  • Jagani Z, Song K, Kutok JL, Dewar MR, Melet A, Santos T, Grassian A, Ghaffari S, Wu C, Yeckes-Rodin H, Rodin HY, Ren R, Miller K, Khosravi-Far R.Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.Cancer Res. 2009 Aug 15;69(16):6546-55.
  • Ren B,Song K,Parangi S,Jin T,Ye M,Humphreys R,Duquette M,Zhang X,Benhaga N,Lawler J,Khosravi-Far R.A double hit to kill tumor and endothelial cells by TRAIL and antiangiogenic 3TSR.Cancer Res. 2009 May 1;69(9):3856-65.
  • Degli Esposti M,Tour J,Ouasti S,Ivanova S,Matarrese P,Malorni W,Khosravi-Far R.Fas death receptor enhances endocytic membrane traffic converging into the Golgi region.Mol Biol Cell. 2009 Jan;20(2):600-15.
  • Matarrese P, Manganelli V, Garofalo T, Tinari A, Gambardella L, Ndebele K, Khosravi-Far R, Sorice M, Degli Esposti M, Malorni W.Endosomal compartment contributes to the propagation of CD95/Fas-mediated signals in type II cells.Biochem J. 2008 Aug 1;413(3):467-78.
  • Plati J, Bucur O, Khosravi-Far R.Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities.J Cell Biochem. 2008 Jul 1;104(4):1124-49. Review.
  • Ndebele K,Gona P,Jin TG,Benhaga N,Chalah A,Degli-Esposti M,Khosravi-Far R.Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced mitochondrial pathway to apoptosis and caspase activation is potentiated by phospholipid scramblase-3.Apoptosis. 2008 Jul;13(7):845-56.
  • Chalah A, Khosravi-Far R.The mitochondrial death pathway.Adv Exp Med Biol. 2008;615:25-45. Review.
  • Jagani Z, Khosravi-Far R.Cancer stem cells and impaired apoptosis.Adv Exp Med Biol. 2008;615:331-44. Review.
  • Melet A, Song K, Bucur O, Jagani Z, Grassian AR, Khosravi-Far R.Apoptotic pathways in tumor progression and therapy.Adv Exp Med Biol. 2008;615:47-79. Review.
  • Jagani Z, Singh A, Khosravi-Far R.FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.Biochim Biophys Acta. 2008 Jan;1785(1):63-84. Review.
  • Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF.c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells.Cancer Res. 2007 Oct 1;67(19):9425-34.
  • Brown L, Ongusaha PP, Kim HG, Nuti S, Mandinova A, Lee JW, Khosravi-Far R, Aaronson SA, Lee SW.CDIP, a novel pro-apoptotic gene, regulates TNFalpha-mediated apoptosis in a p53-dependent manner.EMBO J. 2007 Jul 25;26(14):3410-22.